Preparation and quality control of 211At-labelled and 125I-labelled monoclonal antibodies. Biodistribution in mice carrying human osteosarcoma xenografts

✍ Scribed by Roy H. Larsen; Per Hoff; Jorolf Alstad; Øyvind S. Bruland

• Publisher: John Wiley and Sons
• Year: 1994
• Tongue: French
• Weight: 439 KB
• Volume: 34
• Category: Article
• ISSN: 0022-2135
• DOI: 10.1002/jlcr.2580340811

✦ Synopsis

Abstract

Two anti‐osteosarcoma monoclonal antibodies (TP‐3 IgG and TP‐1 F(ab′)~2~) were labelled with the α‐particle emitting radionuclide ^211^At and, for comparison of stability, with ^125^I using the N‐succinimidyl‐3‐(trimethylstannyl)benzoate intermediate. The quality of the final preparations was measured with immunoreactivity analyses using intact osteosarcoma cells. Immunoreactivity was well retained with values in the range of 65% to 85% for ^211^At‐labelled and ^125^I‐labelled TP‐3 IgG and approximately 60% for both ^211^At‐labelled and ^125^I‐labelled TP‐1 F(ab)~2~. Tumour uptake and retention as well as normal tissue distribution in mice with osteosarcoma xenografts were measured. The uptake of the two radionuclides in tumour was similar, while there was a slight general increase in normal tissue activity at later points for the ^211^At‐labelled MoAbs compared to the ^125^I‐labelled MoAbs, probably caused by a minor release of free ^211^At from the MoAb preparations. The stable retention in tumor tissue demonstrated in this study indicates that ^211^At‐labelled MoAbs may have potential in the treatment of tumours that allow a rapid uptake.